Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile.

dissolution enhancement eutectic mixtures piperine powder diffraction saquinavir small-angle X-ray scattering solid-state characterization

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
11 Oct 2023
Historique:
received: 09 08 2023
revised: 11 09 2023
accepted: 21 09 2023
medline: 28 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

The dissolution rate of the anti-HIV drug saquinavir base (SQV), a poorly water-soluble and extremely low absolute bioavailability drug, was improved through a eutectic mixture formation approach. A screening based on a liquid-assisted grinding technique was performed using a 1:1 molar ratio of the drug and the coformers sodium saccharinate, theobromine, nicotinic acid, nicotinamide, vanillin, vanillic acid, and piperine (PIP), followed by differential scanning calorimetry (DSC). Given that SQV-PIP was the only resulting eutectic system from the screening, both the binary phase and the Tammann diagrams were adapted to this system using DSC data of mixtures prepared from 0.1 to 1.0 molar ratios in order to determine the exact eutectic composition. The SQV-PIP system formed a eutectic at a composition of 0.6 and 0.40, respectively. Then, a solid-state characterization through DSC, powder X-ray diffraction (PXRD), including small-angle X-ray scattering (SAXS) measurements to explore the small-angle region in detail, Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and a powder dissolution test were performed. The conventional PXRD analyses suggested that the eutectic mixture did not exhibit structural changes; however, the small-angle region explored through the SAXS instrument revealed a change in the crystal structure of one of their components. FT-IR spectra showed no molecular interaction in the solid state. Finally, the dissolution profile of SQV in the eutectic mixture was different from the dissolution of pure SQV. After 45 min, approximately 55% of the drug in the eutectic mixture was dissolved, while, for pure SQV, 42% dissolved within this time. Hence, this study concludes that the dissolution rate of SQV can be effectively improved through the approach of using PIP as a coformer.

Identifiants

pubmed: 37896206
pii: pharmaceutics15102446
doi: 10.3390/pharmaceutics15102446
pmc: PMC10609941
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Universidad de Costa Rica
ID : 115-C0-001
Organisme : Universidad de Costa Rica
ID : 115-C3-005
Organisme : Agencia I+D+i (Argentina)
ID : PICT-2020-03759

Références

J Pharm Biomed Anal. 2011 Feb 20;54(3):439-44
pubmed: 20943342
Eur J Pharm Sci. 2010 Nov 20;41(3-4):440-51
pubmed: 20656025
Pharm Res. 2002 Mar;19(3):315-21
pubmed: 11934239
Arch Pharm Res. 2012 Jul;35(7):1187-95
pubmed: 22864741
Cryst Growth Des. 2015 May 6;15(5):2047-2051
pubmed: 28529462
Pharm Res. 2013 Dec;30(12):3225-37
pubmed: 23771564
Pharmaceutics. 2021 Dec 04;13(12):
pubmed: 34959361
Pharmaceutics. 2022 Apr 22;14(5):
pubmed: 35631498
Pharmaceutics. 2019 Mar 09;11(3):
pubmed: 30857331
AAPS PharmSciTech. 2022 Apr 26;23(5):127
pubmed: 35474407
J Am Chem Soc. 2013 Jul 10;135(27):9952-67
pubmed: 23750552
Chem Commun (Camb). 2014 Jan 28;50(8):906-23
pubmed: 24322207
Int J Pharm. 2020 Oct 15;588:119741
pubmed: 32783978
Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):43-57
pubmed: 29250980
Int J Pharm. 2021 Dec 15;610:121203
pubmed: 34673164
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S73-80
pubmed: 11033429
Int J Pharm. 2021 Oct 25;608:121063
pubmed: 34481007
Eur J Pharm Biopharm. 2011 May;78(1):1-9
pubmed: 21266197
Int J Pharm. 2020 May 15;581:119288
pubmed: 32243966
J Pharm Sci. 2007 Feb;96(2):294-304
pubmed: 17051588
AAPS PharmSciTech. 2015 Jun;16(3):528-36
pubmed: 25370024
Adv Drug Deliv Rev. 2007 Jul 30;59(7):603-16
pubmed: 17619064
Pharmaceutics. 2023 Jan 13;15(1):
pubmed: 36678907
Drug Dev Ind Pharm. 2005 May;31(4-5):417-23
pubmed: 16093207
J Pharm Pharmacol. 2017 Mar;69(3):254-264
pubmed: 28134976
Cryst Growth Des. 2009 Jun 3;9(6):2950-2967
pubmed: 19503732
Int J Pharm. 2019 May 30;563:395-405
pubmed: 30978486
ACS Omega. 2020 Apr 21;5(17):9690-9701
pubmed: 32391455
Phytomedicine. 2002 Apr;9(3):224-31
pubmed: 12046863
Adv Drug Deliv Rev. 2007 Jul 30;59(7):617-30
pubmed: 17597252
Acta Pharm Sin B. 2021 Aug;11(8):2537-2564
pubmed: 34522597
Life Sci. 1985 Aug 12;37(6):523-30
pubmed: 4021727

Auteurs

Cinira Fandaruff (C)

Instituto de Tecnologías Emergentes y Ciencias Aplicadas (ITECA), UNSAM-CONICET, Escuela de Ciencia y Tecnología, Laboratorio de Cristalografía Aplicada, Av. 25 de Mayo 1169, San Martín 1650, Provincia de Buenos Aires, Argentina.

María Isabel Quirós-Fallas (MI)

Laboratorio Nacional de Nanotecnología, LANOTEC-CeNAT-CONARE, San José 1174-1200, Costa Rica.
Laboratorio Biodess, Escuela de Química, Universidad de Costa Rica, San Pedro de Montes de Oca, San José 2060, Costa Rica.

José Roberto Vega-Baudrit (JR)

Laboratorio Nacional de Nanotecnología, LANOTEC-CeNAT-CONARE, San José 1174-1200, Costa Rica.

Mirtha Navarro-Hoyos (M)

Laboratorio Biodess, Escuela de Química, Universidad de Costa Rica, San Pedro de Montes de Oca, San José 2060, Costa Rica.

Diego German Lamas (DG)

Instituto de Tecnologías Emergentes y Ciencias Aplicadas (ITECA), UNSAM-CONICET, Escuela de Ciencia y Tecnología, Laboratorio de Cristalografía Aplicada, Av. 25 de Mayo 1169, San Martín 1650, Provincia de Buenos Aires, Argentina.

Andrea Mariela Araya-Sibaja (AM)

Laboratorio Nacional de Nanotecnología, LANOTEC-CeNAT-CONARE, San José 1174-1200, Costa Rica.

Classifications MeSH